全文获取类型
收费全文 | 183209篇 |
免费 | 37700篇 |
国内免费 | 7322篇 |
专业分类
耳鼻咽喉 | 3111篇 |
儿科学 | 3547篇 |
妇产科学 | 2939篇 |
基础医学 | 10587篇 |
口腔科学 | 6610篇 |
临床医学 | 36388篇 |
内科学 | 35433篇 |
皮肤病学 | 3950篇 |
神经病学 | 15597篇 |
特种医学 | 7120篇 |
外国民族医学 | 36篇 |
外科学 | 27304篇 |
综合类 | 19633篇 |
现状与发展 | 60篇 |
一般理论 | 5篇 |
预防医学 | 20552篇 |
眼科学 | 3996篇 |
药学 | 10456篇 |
76篇 | |
中国医学 | 5839篇 |
肿瘤学 | 14992篇 |
出版年
2024年 | 1003篇 |
2023年 | 6008篇 |
2022年 | 3723篇 |
2021年 | 6045篇 |
2020年 | 8044篇 |
2019年 | 4195篇 |
2018年 | 9137篇 |
2017年 | 9681篇 |
2016年 | 10042篇 |
2015年 | 11526篇 |
2014年 | 14938篇 |
2013年 | 16795篇 |
2012年 | 10590篇 |
2011年 | 10781篇 |
2010年 | 12315篇 |
2009年 | 13903篇 |
2008年 | 8991篇 |
2007年 | 7776篇 |
2006年 | 8620篇 |
2005年 | 6717篇 |
2004年 | 5114篇 |
2003年 | 5136篇 |
2002年 | 4386篇 |
2001年 | 4516篇 |
2000年 | 3286篇 |
1999年 | 3225篇 |
1998年 | 2951篇 |
1997年 | 2795篇 |
1996年 | 2604篇 |
1995年 | 2279篇 |
1994年 | 1592篇 |
1993年 | 1230篇 |
1992年 | 1157篇 |
1991年 | 981篇 |
1990年 | 835篇 |
1989年 | 812篇 |
1988年 | 732篇 |
1987年 | 585篇 |
1986年 | 516篇 |
1985年 | 452篇 |
1984年 | 312篇 |
1983年 | 355篇 |
1982年 | 253篇 |
1981年 | 230篇 |
1980年 | 126篇 |
1978年 | 131篇 |
1977年 | 123篇 |
1976年 | 90篇 |
1974年 | 90篇 |
1972年 | 86篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
11.
目的探讨脊髓小脑共济失调2型(SCA2)致病基因ATXN2异常等位基因中间重复个体的表型和分子遗传学特点。方法针对2005—2018年中日友好医院神经科运动障碍与神经遗传病研究中心收集的1383个常染色体显性遗传共济失调家系的先证者和部分家系成员,采用荧光标记毛细管电泳片段分析方法进行动态突变检测,对携带ATXN2基因中间重复的个体进行临床表型和遗传特征分析。结果共检出163个家系(包含先证者和家系成员共203人)携带异常扩展的ATXN2基因CAG重复序列,其中93个家系中有107例的异常扩展等位基因重复次数在29~34次之间。在其中的20个亲子对中,父系遗传16个,异常等位基因的代间扩展增加0~28次,母系遗传4个,异常等位基因的代间扩展增加0~4次。结论对于临床拟诊SCA2家系患者,需对其亲代或成年子代个体进行ATXN2基因检测,以免漏诊。动态突变基因检测有助于识别中间重复的个体,对明确家系致病基因和遗传咨询至关重要。 相似文献
12.
13.
14.
15.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
16.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
17.
18.
19.
20.